Sign In
Buy CTMX
$3.16
-0.290 (-8.41%)
At Close: Jun 02, 2026
CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript
06:10pm, Friday, 08'th Aug 2025
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.
CytomX Therapeutics: Updated Outlook For Late 2025
05:05pm, Friday, 08'th Aug 2025
I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer
CytomX (CTMX) Q2 Revenue Drops 26%
06:29pm, Thursday, 07'th Aug 2025
CytomX (CTMX) Q2 Revenue Drops 26%
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
06:26pm, Thursday, 07'th Aug 2025
CytomX Therapeutics (CTMX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
04:10pm, Thursday, 07'th Aug 2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
08:00am, Thursday, 31'st Jul 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean Mc
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the fir
CytomX Therapeutics: Doubling Overnight On Phase 1 Data
10:34am, Tuesday, 13'th May 2025
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)
02:40pm, Monday, 12'th May 2025
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden -
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
11:11am, Monday, 12'th May 2025
CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
08:26am, Monday, 12'th May 2025
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
06:50am, Monday, 12'th May 2025
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced t
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
06:15am, Monday, 12'th May 2025
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) -
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and 10 mg/kg Q3W) -
